Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Plexxikon has treated the first patient in a Phase II clinical trial evaluating PLX3397 as a treatment for Hodgkin lymphoma.
Subscribe to our email newsletter
PLX3397 is an oral, selective inhibitor that down-modulates two key cell types, macrophages and mast cells, that are thought to mediate the progression of Hodgkin lymphoma tumours.
The multi-centre, single-arm trial is expected to enroll approximately 30 patients with Hodgkin lymphoma who have relapsed or become refractory to standard therapies.
The trial will evaluate the efficacy of orally administered PLX3397 as measured by overall response rate.
The trial will also assess the duration of response, the disease control rate, progression-free survival, response biomarkers and overall safety.
Plexxikon plans to explore potential efficacy of PLX3397 in additional trials to be initiated in 2011.
These trials will focus on recurrent glioblastoma multiforme, mutated relapsed acute myelogenous leukaemia (AML) and metastatic breast cancer.